Navigation Links
Al Novak Elected Chairman of the Board of OrbusNeich Medical

HONG KONG, Dec. 9 /PRNewswire/ -- OrbusNeich today announced that Al Novak has been elected chairman of the board.

Novak, 61 years old, will continue to serve as president and chief executive officer of OrbusNeich, the role that he has held since 2008. He brings over 27 years of leadership experience in the medical technology industry to the position having served as chief executive officer of Novoste Corporation and Biosense, Inc. and in marketing and financial positions with Cordis Corporation including vice president and chief financial officer. Mr. Novak was a founder of Syntheon LLC and also serves on the board of directors of Cyberonics Inc., a NASDAQ listed company.

"Al Novak's election as chairman comes at an important time in the growth of OrbusNeich as a global medical device company," said Teddy Chien, the company's former chairman who will remain a board member and chairman emeritus. "We are confident that Al will continue to lead this company toward additional expansion and the development of competitive, innovative technology that meets the needs of interventional cardiologists."

Novak added: "We are grateful to Teddy for his commitment to OrbusNeich and for his many contributions to interventional cardiology. His vision of building a global medical device company that capitalizes on distinct geographical opportunities based on local market expertise and relationships is one that will continue to drive our business."

Teddy Chien has had a distinguished career working with the medical community over the past 50 years in various capacities at pharmaceutical and medical device companies. In 1979, Chien founded Neich Medical as the exclusive representative for Cordis Corporation in Asia, which was subsequently sold to Johnson and Johnson when it acquired Cordis in 1996. Neich Medical was relaunched in 1999 with the vision to design and build its own cardiology products. Neich Medical and Orbus Medical Technologies merged in 2005 to form OrbusNeich Medical.

Mr. Chien has made many contributions to the cardiology community. He is most proud of founding, in conjunction with leading cardiologists in the Asia/Pacific region, The Chien Foundation. The Foundation was established to provide cardiology fellowships in developing countries in Asia and to foster goodwill and training opportunities among interventional cardiologists within the region. The Foundation also supports keynote lectures and Young Investigator Awards at major conferences within Asia.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Bio-engineered R stent, as well as stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent, Scoreflex(TM), SafeCut(TM), Sapphire(TM), Sapphire NC, Avita(TM), Avita HP and Lumina(TM). OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo, Japan; and Shenzhen, China. OrbusNeich, which has provided medical devices to physicians through its predecessor companies since 1979, supplies products today to interventional cardiologists in more than 60 countries. For more information, visit

SOURCE OrbusNeich

SOURCE OrbusNeich
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Daniel K. Spiegelman Elected to Board of Directors of Omeros
2. Omnicell Selected by Nations Third Largest Public Healthcare System for Medication Management Systems
3. Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries
4. Mylans President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
5. Zyomyx Point-of-Care CD4 Test Selected by CD4 Initiative to Help Treat HIV/AIDS Patients in Developing Countries
6. Varian Medical Systems Selected to Supply Major Project to Bring Advanced Radiotherapy Treatments to North of Portugal
7. Sanovia Selected to Deliver PA-Logic(TM) Pharmaceutical Prior Authorization Platform to HealthSpring
8. A Unique Endoluminal Approach for the Treatment of Morbid Obesity Selected for Presentation at the 2009 American College of Surgeons Clinical Congress
9. Fresenius Medical Care, N.A. Has Selected VitalRemedyMDs VitalProteinRx(TM) As Its Bar of Choice for Protein Replacement in Dialysis Patients
10. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
11. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
Post Your Comments:
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
(Date:6/23/2016)... June 23, 2016 , , ... July 7, 2016 , , , , LOCATION: , , ... , , , EXPERT PANELISTS:  , , , Frost & ... Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, ... The global pharmaceutical industry is witnessing an exceptional era. Several new ...
(Date:6/23/2016)... -- Guerbet announced today that it has been named a ... One of 12 suppliers to receive the ... of Premier members through exceptional local customer service and ... lower costs. "We ... customer service from Premier," says Massimo Carrara , ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from reveals that behind the tendency to set ...
Breaking Medicine News(10 mins):